12:00 AM
Jun 17, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

LY2886721: Phase II discontinued

Eli Lilly discontinued the double-blind, placebo-controlled, international Phase II BACC trial evaluating once-daily 15, 35 and 70 mg doses of oral LY2886721 for 26 weeks in patients with AD after cases of abnormal liver biochemical tests were identified as part of routine monitoring. The trial...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >